ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis

Wang, Ren; Lian, Jie; Wang, Xin; Pang, Xiangyi; Xu, Benjie; Tang, Shuli; Shao, Jiayue; Lu, Haibo*哈尔滨医科大学
BIOMOLECULES AND BIOMEDICINE2023DOI: 10.17305/bjbms.2022.8286
4被引7阅读
引用收藏
分享

摘要

Some patients with microsatellite instability-high colorectal cancer (MSI-H CRC) have shown a poor response to immunotherapy in clinical trials. We investigated the intrinsic resistance to and efficacy of immunotherapy in patients with MSI-H CRC. The PubMed and Web of Science databases were searched using keywords such as "colorectal cancer," "immunotherapy," and "clinical experiment." Random-effects models were used to generate the combined complete response, partial response, stable disease, progressive disease, objective response rate (ORR), disease control rate (DCR), and incidence of adverse events. We then performed a subgroup analysis based on the ORR and incidence of intrinsic resistance. The meta-analysis included seven clinical trials. The incidences of complete response, partial response, stable disease, and progressive disease summarized by the random-effects model were 8%, 37%, 26%, and 25%, respectively. The ORR and DCR were 45% and 71%, respectively. The ORRs of programmed cell death protein 1 inhibitor (anti-PD-1), programmed death ligand 1 inhibitor (anti-PD-L1), and anti-PD-1 combined with cytotoxic T lymphocyte-associated antigen 4 inhibitor (anti-CTLA-4) immunotherapy were 38%, 54%, and 57%, respectively. The ORR of immune checkpoint inhibitors for first-and third-line therapy was 56% and 32%, respectively. Dual-drug immunotherapy significantly reduced the incidence of intrinsic resistance to immunotherapy (12% vs 31%). The incidences of intrinsic resistance to first-line therapy and second-line and later therapy were 29% and 26%, respectively. Approximately 25% of patients with MSI-H CRC had intrinsic resistance to immunotherapy. Anti-PD-1 combined with anti-CTLA-4 significantly increased the ORR, thereby reducing the incidence of intrinsic resistance. Moving immunotherapy into earlier lines of therapy, although not reducing the incidence of intrinsic resistance, can improve the ORR in patients with MSI-H CRC.

学科与关键词

关键词
Colorectal cancer (CRC)microsatellite instability-high (MSI-H)intrinsic resistanceefficacyimmunotherapy
相关
加载中…
  • How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
    Wang, Qianyu; Shen, Xiaofei; Chen, Gang*; Du, Junfeng*International Journal of Cancer, 2023, 153(4): 709-722.被引 1
  • Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy
    Yi, Jiahong; Xue, Ju; Yang, Lin; Xia, Liangping*; He, Wenzhuo*Frontiers in Nutrition, 2023, 10: 1094189.被引 3
  • Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors
    Zhang, Jinli; Yang, Lu; Kong, Fanwei; Wu, Di; Hu, Baoru; Yang, Jie; He, Jiaxin; Liu, Lei*Frontiers in Medicine, 2023, 10: 1051034.
查看全部 →

发表信息

论文状态
公开发表
期刊
BIOMOLECULES AND BIOMEDICINE
发表日期
2023
卷期
第 23 卷, 第 2 期
页码
198-208
DOI
10.17305/bjbms.2022.8286
成果收录
SCIE
资助标注
National Natural Science Foundation of China [U20A20376, 61972116]; Beijing Award Foundation [YXJL-2020-0818-0478]; Wu Jieping Medical Foundation [320.6750.2020-19-20]; Heilongjiang Province Postdoctoral Funding Project [LBH-Z21189]; Harbin Medical University Innovative Science Research Funded Project [31041220028]; China Postdoctoral Science Foundation [2022MD713747]

作者

  • W

    Wang, Ren (第一作者)

    harbin med univ

  • L

    Lian, Jie

    harbin med univ

查看全部 8 位作者收起作者
  • W

    Wang, Xin

    harbin med univ

  • P

    Pang, Xiangyi

    harbin med univ

  • X

    Xu, Benjie

    harbin med univ

  • T

    Tang, Shuli

    harbin med univ

  • S

    Shao, Jiayue

    harbin med univ

  • L

    Lu, Haibo (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417